Innoviva (INVA) Assets Average (2011 - 2026)
Innoviva's (INVA) quarterly Assets Average came in at $1.7 billion in Q1 2026, up 35.86% YoY from $1.3 billion in Q1 2025, and up 13.3% on a QoQ basis from $1.5 billion in Q4 2025.
Analysis
Innoviva (INVA) Assets Average (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 16 years of Assets Average data on file, last reported at $1.7 billion in Q1 2026.
- Quarterly Assets Average rose 35.86% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 35.86% YoY) and the FY2025 annual result came in at $1.5 billion, up 20.99% from the prior year.
- Assets Average advanced to $1.7 billion in Q1 2026, from $1.5 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $1.7 billion in Q1 2026 to a low of $1.0 billion in Q1 2022.
- A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average surged 47.06% — and 2023, when it retreated 6.45%.
- Tracing INVA's Assets Average over 5 years: stood at $1.3 billion in 2022, then retreated by 4.99% to $1.2 billion in 2023, then climbed by 4.16% to $1.3 billion in 2024, then climbed by 20.99% to $1.5 billion in 2025, then gained by 13.3% to $1.7 billion in 2026.
- The last three Assets Average figures came in at $1.7 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 1.77 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Bn |
| Mar 31, 2026 | 1.74 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | 1.28 Bn |
| Dec 31, 2024 | 1.27 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.26 Bn |
| Dec 31, 2023 | 1.22 Bn |
| Sep 30, 2023 | 1.15 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.18 Bn |
| Dec 31, 2022 | 1.28 Bn |
| Sep 30, 2022 | 1.23 Bn |
| Jun 30, 2022 | 1.12 Bn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 906.82 Mn |
| Sep 30, 2021 | 838.19 Mn |